These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life. Baysal M; Ümit EG; Kırkızlar HO; Özdöver AC; Demir AM Turk J Haematol; 2019 Feb; 36(1):43-47. PubMed ID: 29880465 [TBL] [Abstract][Full Text] [Related]
4. Thalidomide Effects in Patients with Hereditary Hemorrhagic Telangiectasia During Therapeutic Treatment and in Fli-EGFP Transgenic Zebrafish Model. Peng HL; Yi YF; Zhou SK; Xie SS; Zhang GS Chin Med J (Engl); 2015 Nov; 128(22):3050-4. PubMed ID: 26608985 [TBL] [Abstract][Full Text] [Related]
7. Thalidomide for Epistaxis in Patients with Hereditary Hemorrhagic Telangiectasia: A Preliminary Study. Fang J; Chen X; Zhu B; Ye H; Zhang W; Guan J; Su K Otolaryngol Head Neck Surg; 2017 Aug; 157(2):217-221. PubMed ID: 28418273 [TBL] [Abstract][Full Text] [Related]
8. Thalidomide Reduces Hemorrhage of Brain Arteriovenous Malformations in a Mouse Model. Zhu W; Chen W; Zou D; Wang L; Bao C; Zhan L; Saw D; Wang S; Winkler E; Li Z; Zhang M; Shen F; Shaligram S; Lawton M; Su H Stroke; 2018 May; 49(5):1232-1240. PubMed ID: 29593101 [TBL] [Abstract][Full Text] [Related]
9. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia. Zarrabeitia R; Ojeda-Fernandez L; Recio L; Bernabéu C; Parra JA; Albiñana V; Botella LM Thromb Haemost; 2016 Jun; 115(6):1167-77. PubMed ID: 26818701 [TBL] [Abstract][Full Text] [Related]
10. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064 [TBL] [Abstract][Full Text] [Related]
11. Deep vein thrombosis induced by thalidomide to control epistaxis secondary to hereditary haemorrhagic telangiectasia. Penaloza A; Vekemans MC; Lambert C; Hermans C Blood Coagul Fibrinolysis; 2011 Oct; 22(7):616-8. PubMed ID: 21885956 [TBL] [Abstract][Full Text] [Related]
12. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. Harrison L; Kundra A; Jervis P J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary arteriovenous malformations etiologies in HHT patients and potential utility of thalidomide. Lacout A; Marcy PY; El Hajjam M; Lacombe P Med Hypotheses; 2013 May; 80(5):587-8. PubMed ID: 23452644 [TBL] [Abstract][Full Text] [Related]
14. Oral itraconazole for epistaxis in hereditary hemorrhagic telangiectasia: a proof of concept study. Kroon S; Snijder RJ; Hosman AE; Vorselaars VMM; Disch FJM; Post MC; Mager JJ Angiogenesis; 2021 May; 24(2):379-386. PubMed ID: 33211216 [TBL] [Abstract][Full Text] [Related]